KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -$22.5 million.

  • Amneal Pharmaceuticals' Cash from Investing Activities fell 8.46% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.9 million, marking a year-over-year decrease of 5.39%. This contributed to the annual value of -$63.0 million for FY2024, which is 8.95% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$22.5 million for Q3 2025, which was up 15.38% from -$26.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$6.5 million during Q2 2024, with a 5-year trough of -$97.4 million in Q1 2022.
  • Its 3-year average for Cash from Investing Activities is -$18.1 million, with a median of -$17.8 million in 2025.
  • Examining YoY changes over the last 5 years, Amneal Pharmaceuticals' Cash from Investing Activities showed a top increase of 95.16% in 2021 and a maximum decrease of 828.50% in 2021.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$87.0 million in 2021, then surged by 86.82% to -$11.5 million in 2022, then crashed by 176.40% to -$31.7 million in 2023, then spiked by 49.33% to -$16.1 million in 2024, then fell by 8.46% to -$22.5 million in 2025.
  • Its Cash from Investing Activities stands at -$22.5 million for Q3 2025, versus -$26.5 million for Q2 2025 and -$17.8 million for Q1 2025.